FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000060919> ?p ?o ?g. }

• W3000060919 endingPage "114" @default.
• W3000060919 startingPage "113" @default.
• W3000060919 abstract "Large-scale genetic studies have identified hundreds of robust statistical associations between genetic variants and risk for mental disorders, including depression1 and schizophrenia2. These findings provide clear evidence for a polygenic architecture of those disorders, i.e., disease risk is influenced by thousands of genetic variants with individually small effects. Due to the polygenic nature of mental disorders, the actual gene mechanisms underlying the pathophysiological pathways remain largely unknown. A key challenge is to elucidate the downstream molecular consequences underlying the genetic associations. Here we illustrate the value of integrating genetics and transcriptomics (i.e., the study of the level and regulation of gene expression in human cells) and how this approach has improved our understanding of the biological mechanisms underlying psychiatric disease risk. We further discuss how this methodology may contribute to developing improved therapeutics for mental disorders. Determining the downstream molecular consequences of genetic risk factors for psychiatric disease is challenging for two reasons. First, the majority of disease-associated genetic risk factors are located in non-coding regions of the genome, suggesting that these genetic variants act through the regulation of gene expression rather than by directly altering the protein product. Second, due to extensive linkage disequilibrium (LD) in the genome, genetic studies alone are unable to distinguish causal variants from correlated non-functional variants within an LD block. Indeed, the genetic variant may only be statistically correlated with disease risk and may therefore not provide useful information on the causal disease mechanisms. Therefore, it is important to extend genetic studies by integrating functionally relevant intermediate measures reflecting molecular disease mechanisms (i.e., gene expression). To this end, Gamazon et al3 have developed a novel method that integrates genetic and transcriptomic information. This approach, referred to as PrediXcan, is the first transcriptome-wide association study (TWAS) methodology and allows researchers to identify genes whose expression is significantly associated with disease risk. It utilizes genotype and gene expression data from a reference panel to determine the regulatory effects of genetic variants and to identify which genes are differentially expressed in patients compared to healthy controls. An example of a widely used reference panel is the GTEx resource4, which links genotype data to gene expression levels in 48 tissues from 714 donors, including 13 brain regions from 216 donors. TWAS methods, such as PrediXcan, have multiple advantages. First, use of genetically-determined gene expression from a psychiatrically healthy reference panel ensures that significant associations are not influenced by potential confounders. For example, disease-associated variables (such as the use of psychotropic drugs) may lead to differences in gene expression that are a consequence rather than a cause of psychiatric disease. Second, TWAS methods do not only identify differentially expressed genes between patients and controls, but also provide information on the direction of effect, by showing whether the expression of a gene is upregulated or downregulated in patients compared to controls. Third, the effect of a genetic variant on gene expression may be tissue-specific. TWAS allows researchers to investigate the tissue-specificity of genetic effects. For example, we have previously shown that the strongest enrichment of genetic effects on gene expression was observed in disease-relevant tissues (e.g., aortic artery for systolic blood pressure and hippocampus for Alzheimer's disease)5. We have recently integrated genetic and transcriptomic data for four mental disorders (schizophrenia, bipolar disorder, major depression and attention-deficit/hyperactivity disorder) to gain pathophysiological insights into the role of the brain, adrenal gland (neuroendocrine factors), and colon (gastrointestinal systems)6. We found novel genetic mechanisms underlying disease risk and identified putative causal genes. Interestingly, our analysis detected 70 genes that were not identified in the original genetic analyses, illustrating improved power of TWAS compared to genome wide association studies (GWAS). Our findings highlighted the importance of analyzing gene expression data collected in multiple tissues (beyond easily accessible whole blood samples), as 76% of the putative causal genes were detected only in difficult-to-acquire tissues such as the brain. Integration of genetic and transcriptomic data will provide excellent opportunities to produce improved therapeutics for mental disorders. Genetic discoveries may accelerate drug repositioning by identifying genes that are targeted by existing pharmaceutical compounds, an approach known as drug repurposing7, 8. The development of a new drug takes on average 13-15 years and costs $2.5-3.5 billion, with only a ~10% chance that a new therapy will be successfully approved by government regulatory agencies. In contrast, drug repurposing allows increased efficiency and lower costs, because candidates have already established safety profiles from Phase I clinical trials, with time to approval estimated at 6.5 years at an average cost of $350 million. Drugs that have been linked to disorders through genetic studies are reported to be twice as likely to be clinically approved compared to drugs with no such links7. TWAS adds value beyond genetics as it provides essential information on whether a drug is predicted to reverse patterns of gene expression in patients and may therefore be able to reverse the disease phenotype. For example, if a disease-associated gene shows downregulated levels of gene expression in patients, we might aim to identify a drug that increases the expression of that gene, while drugs that decrease the expression may not be beneficial or even worsen disease symptoms. So et al9, using PrediXcan, identified a number of repurposing candidates, many of which were relevant to mental disorders. We expect that future studies exploring drugs with different mechanisms of action will reveal drug candidates that are not yet prescribed for the treatment of psychiatric disease (e.g., immune response drugs). In conclusion, large-scale genetic studies provide a wealth of information of direct clinical relevance. Integration with other types of -omics data will be essential to elucidating biological mechanisms, identification of novel drugs, and translation of findings into the clinic." @default.
• W3000060919 created "2020-01-23" @default.
• W3000060919 creator A5068110851 @default.
• W3000060919 creator A5091036407 @default.
• W3000060919 date "2020-01-10" @default.
• W3000060919 modified "2023-10-01" @default.
• W3000060919 title "Transcriptome‐wide association analysis offers novel opportunities for clinical translation of genetic discoveries on mental disorders" @default.
• W3000060919 cites W2118822739 @default.
• W3000060919 cites W2209106767 @default.
• W3000060919 cites W2749491127 @default.
• W3000060919 cites W2761275051 @default.
• W3000060919 cites W2777388159 @default.
• W3000060919 cites W2792278586 @default.
• W3000060919 cites W2811205482 @default.
• W3000060919 cites W2911487850 @default.
• W3000060919 cites W2945399202 @default.
• W3000060919 doi "https://doi.org/10.1002/wps.20702" @default.
• W3000060919 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6953546" @default.
• W3000060919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31922671" @default.
• W3000060919 hasPublicationYear "2020" @default.
• W3000060919 type Work @default.
• W3000060919 sameAs 3000060919 @default.
• W3000060919 citedByCount "4" @default.
• W3000060919 countsByYear W30000609192021 @default.
• W3000060919 countsByYear W30000609192022 @default.
• W3000060919 countsByYear W30000609192023 @default.
• W3000060919 crossrefType "journal-article" @default.
• W3000060919 hasAuthorship W3000060919A5068110851 @default.
• W3000060919 hasAuthorship W3000060919A5091036407 @default.
• W3000060919 hasBestOaLocation W30000609191 @default.
• W3000060919 hasConcept C104317684 @default.
• W3000060919 hasConcept C106208931 @default.
• W3000060919 hasConcept C135763542 @default.
• W3000060919 hasConcept C142724271 @default.
• W3000060919 hasConcept C153209595 @default.
• W3000060919 hasConcept C180754005 @default.
• W3000060919 hasConcept C186413461 @default.
• W3000060919 hasConcept C197754878 @default.
• W3000060919 hasConcept C2779134260 @default.
• W3000060919 hasConcept C35605836 @default.
• W3000060919 hasConcept C54355233 @default.
• W3000060919 hasConcept C60644358 @default.
• W3000060919 hasConcept C70721500 @default.
• W3000060919 hasConcept C71924100 @default.
• W3000060919 hasConcept C81941488 @default.
• W3000060919 hasConcept C86803240 @default.
• W3000060919 hasConcept C9287583 @default.
• W3000060919 hasConceptScore W3000060919C104317684 @default.
• W3000060919 hasConceptScore W3000060919C106208931 @default.
• W3000060919 hasConceptScore W3000060919C135763542 @default.
• W3000060919 hasConceptScore W3000060919C142724271 @default.
• W3000060919 hasConceptScore W3000060919C153209595 @default.
• W3000060919 hasConceptScore W3000060919C180754005 @default.
• W3000060919 hasConceptScore W3000060919C186413461 @default.
• W3000060919 hasConceptScore W3000060919C197754878 @default.
• W3000060919 hasConceptScore W3000060919C2779134260 @default.
• W3000060919 hasConceptScore W3000060919C35605836 @default.
• W3000060919 hasConceptScore W3000060919C54355233 @default.
• W3000060919 hasConceptScore W3000060919C60644358 @default.
• W3000060919 hasConceptScore W3000060919C70721500 @default.
• W3000060919 hasConceptScore W3000060919C71924100 @default.
• W3000060919 hasConceptScore W3000060919C81941488 @default.
• W3000060919 hasConceptScore W3000060919C86803240 @default.
• W3000060919 hasConceptScore W3000060919C9287583 @default.
• W3000060919 hasIssue "1" @default.
• W3000060919 hasLocation W30000609191 @default.
• W3000060919 hasLocation W30000609192 @default.
• W3000060919 hasLocation W30000609193 @default.
• W3000060919 hasLocation W30000609194 @default.
• W3000060919 hasOpenAccess W3000060919 @default.
• W3000060919 hasPrimaryLocation W30000609191 @default.
• W3000060919 hasRelatedWork W1963934068 @default.
• W3000060919 hasRelatedWork W2032457672 @default.
• W3000060919 hasRelatedWork W2032714982 @default.
• W3000060919 hasRelatedWork W2112153462 @default.
• W3000060919 hasRelatedWork W2258027821 @default.
• W3000060919 hasRelatedWork W2469213152 @default.
• W3000060919 hasRelatedWork W2517753256 @default.
• W3000060919 hasRelatedWork W2951734666 @default.
• W3000060919 hasRelatedWork W4200296575 @default.
• W3000060919 hasRelatedWork W4223440595 @default.
• W3000060919 hasVolume "19" @default.
• W3000060919 isParatext "false" @default.
• W3000060919 isRetracted "false" @default.
• W3000060919 magId "3000060919" @default.
• W3000060919 workType "article" @default.